Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Biopredictions Webinar (January 2022)
13 slides from Genetic Signatures's conference presentation, Jan 27, 2022
Slide 1: Investor Presentation January 2022
Investor Presentation JANUARY 2022
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer SEPTEMBER JANUARY 2022 2021 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation conce
Slide 3: Company Summary
Investor DOCUMENT Presentation TITLE SEPTEMBER JANUARY 2022 2021 Company Summary Novel 3base™ technology – rapid, low cost and accurate EasyScreen™ test kits available for sale in most major markets 2Q FY22 sales $9.4m up 16% pcp, $21.8m 1H FY22 YoY growth since listing ‒ 4 year CAGR 93% Customers –
Slide 4: EasyScreen Detection Kits
Trusted & Proven Technology Investor DOCUMENT Presentation SEPTEMBER TITLE JANUARY 2022 2021 A ‘Syndromic Screening’ approach allows users to test a broad range of clinically relevant pathogens based on patient symptoms, helping clinicians make an accurate diagnosis EasyScreen™ Detection Kits Stream
Slide 5: Financial Summary – Sales
Investor DOCUMENT Presentation TITLE Financial Summary – Sales SEPTEMBER JANUARY 2022 2021 Revenue from sales (A$m) Continued Strong Revenue Growth 28.3 Q2 FY22 $9.4m (unaudited), up 16% on pcp Strong local demand for COVID tests continue 5.4 due to ongoing outbreaks 21.8 4.2 International sales tea
Slide 6: Financial Summary – Cashflow
Investor DOCUMENT Presentation TITLE Financial Summary – Cashflow SEPTEMBER JANUARY 2022 2021 A'000s 2Q FY22 1H FY22 Planned use of funds Receipts from customers 12,084 22,424 Instrument development - $10-12m Payments to suppliers and employees (7,325) (14,627) Future US FDA clearances Other 76 80 N
Slide 7: EasyScreen Detection Kit Range
Investor DOCUMENT Presentation TITLE EasyScreenTM Detection Kit Range SEPTEMBER JANUARY 2022 2021 Registrations Current In process Enteric * Detects 20+ gastroenteritis pathogens including Salmonella, Giardia and Norovirus Respiratory US EUA Detects 14 common respiratory infections including Influen
Slide 8: SARS-CoV-2 Update
Investor DOCUMENT Presentation TITLE SARS-CoV-2 Update SEPTEMBER JANUARY 2022 2021 New variant of concern – Omicron – declared by WHO EasyScreen™ SARS-CoV-2 Detection Kit shown to detect all known variants1, including Omicron & Delta TGA registers saliva-based protocol for sample collection South Af
Slide 9: FDA 510(k) Clearance Program
Investor DOCUMENT Presentation TITLE FDA 510(k) Clearance Program SEPTEMBER JANUARY 2022 2021 Market Dynamics Est. 5.5m Enteric Protozoan tests pa in the US Initial focus on largest 30 “high throughput” centralised labs Smaller decentralised labs more accessible with development of new testing hardw
Slide 10: Investment Summary
Investor DOCUMENT Presentation TITLE Investment Summary SEPTEMBER JANUARY 2022 2021 Financial information Share price (25-Jan-21) A$1.29 Shares on issue 143.0m Market capitalisation A$184.6m Ave monthly turnover (shares) 1.9m Cash (30-Dec-21) A$37.5m Debt (30-Dec-21) Nil Enterprise value A$147.1m To
Slide 11: Next Steps – Beyond COVID
Next Steps – Beyond COVID Investor DOCUMENT Presentation SEPTEMBER TITLE JANUARY 2022 2021 Leverage COVID-19 – new customers, new tests Continue building interest in EasyScreenTM kits in US & EU markets using expanded sales teams and SARS-CoV-2 experience as leverage Targeting high throughput pathol
Slide 12: Reasons to Invest
Reasons to Invest Investor DOCUMENT Presentation SEPTEMBER TITLE JANUARY 2022 2021 Attractive investment proposition Continued product • Business model with expansion favourable unit economics • 5 product groups in • Increasing international Significant market development recognition via opportuniti
Slide 13: Contact us
Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 13
Genetic Signatures — Biopredictions Webinar (January 2022) on 6ix